Form 8-K - Current report
December 15 2023 - 5:00PM
Edgar (US Regulatory)
false
0001858685
0001858685
2023-12-12
2023-12-12
0001858685
BFRI:CommonStockParValue0.001PerShareMember
2023-12-12
2023-12-12
0001858685
BFRI:PreferredStockPurchaseRightsMember
2023-12-12
2023-12-12
0001858685
BFRI:WarrantsToPurchaseCommonStockMember
2023-12-12
2023-12-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): December 12, 2023
Biofrontera
Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40943 |
|
47-3765675 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
120
Presidential Way, Suite 330
Woburn,
Massachusetts |
|
01801 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (781) 245-1325
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class |
|
Trading Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock, par value $0.001 per share |
|
BFRI |
|
The
Nasdaq Stock Market LLC |
Preferred
Stock Purchase Rights |
|
|
|
The
Nasdaq Stock Market LLC |
Warrants
to purchase common stock |
|
BFRIW |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (the “Exchange Act”) (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
1.01 |
Entry into a Material Definitive Agreement. |
On
December 12, 2023, Biofrontera Inc. (the “Company”) entered into an addendum (the “Addendum”) to
its Amended and Restated License and Supply Agreement, dated as of June 16, 2021 (as amended on October 8, 2021, the “LSA”),
by and among the Company, Biofrontera Pharma GmbH (“Pharma”), and Biofrontera Bioscience GmbH (“Bioscience”).
The Addendum provides, among other things, for a schedule of payments in relation to various financial obligations among the Company,
Pharma, Bioscience, and Biofrontera AG (the parent company of Pharma and Bioscience), including updated terms relating to payments by
the Company to Pharma for purchases of Licensed Products (as that term is defined in the LSA) under the LSA through the end of 2024.
This description of the Addendum does not purport to be complete and is qualified in its entirety by reference to the full text of the
Addendum, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item
9.01 |
Financial
Statements and Exhibits. |
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
December
15, 2023
(Date) |
Biofrontera
Inc.
(Registrant) |
|
|
|
/s/
E. Fred Leffler III |
|
E.
Fred Leffler III |
|
Chief
Financial Officer |
Exhibit
10.1
Addendum
to Amended and Restated License and Supply Agreement
This
Addendum to Amended and Restated License and Supply Agreement (the “Addendum”) is made effective as of December 5, 2023,
by and between Biofrontera AG (“AG”), Biofrontera Pharma GmbH (“PHARMA”), and Biofrontera Bioscience GmbH (“BIOSCIENCE”),
each a German corporation/company with its principal offices at Hemmelrather Weg 201, 51377 Leverkusen, Germany, and Biofrontera Inc.,
a Delaware corporation with its principal place of business at 120 Presidential Way, Woburn, MA 01801, USA (“INC”). AG, PHARMA,
BIOSCIENCE, and INC may collectively be referred to as the “Parties” or individually as a “Party.” Capitalized
terms used but not defined herein shall have the meanings assigned to them in the Agreement, as defined below.
Recitals
Whereas,
PHARMA, BIOSCIENCE, and INC have entered into an Amended and Restated License and Supply Agreement, dated as of June 16, 2021, as amended
by that certain Corrected Amendment to Amended and Restated License and Supply Agreement, dated as of October 8, 2021(collectively, the
“Agreement”);
Whereas,
the Parties wish to add additional terms to the Agreement in regard to certain mutual payment obligations between the Parties, as described
below; and
Now,
therefore, in consideration of the foregoing and the agreements contained herein, the Parties hereto, intending to be legally bound hereby,
agree as follows:
Agreement
1. |
Payment Obligations. This
Addendum pertains to the payment of the following obligations of each of the Parties (collectively, the “Payment Obligations”): |
|
a. |
INC’s
payment of Invoice No. DARM00429 to PHARMA; |
|
|
|
|
b. |
INC’s
payment of Invoice No. AR01207 (as adjusted to reflect termination of IT services on December 19, 2022) to PHARMA; |
|
|
|
|
c. |
INC’s
payment of Invoices No DARM0043, DARM00444, DARM00484 to PHARMA; |
|
|
|
|
d. |
INC’s
payment of invoices No TAR01584 and No.TAR01593 (services issues) to BIOSCIENCE; |
|
|
|
|
e. |
BIOSCIENCE’s
payment of Invoice Nos. BioSci 2023-Q3, BioSci 2023-10, and BioSci 2023-09 to INC; |
|
|
|
|
f. |
INC’s
payment of an invoice to be issued by PHARMA in relation to PO #11440 (for the purchase of Ameluz); |
|
|
|
|
g. |
AG’s
reimbursement of its 50% share of the “Third Installment” payment under a certain “Amended Settlement Allocation
Agreement” between INC and AG dated March 31, 2023 to INC; |
|
|
|
|
h. |
INC’s
payment of the purchase price variance as described in Section 6.5 of the Agreement for the year ending December 31, 2023 (“2023
PPV”) to PHARMA; |
|
i. |
INC’s
payments of invoices to be issued by PHARMA in relation to POs #11272, #11305, and #11154; and |
|
|
|
|
j. |
BIOSCIENCE’s
payment of invoices to be issued by INC in relation to clinical services provided to BIOSCIENCE in Q4 2023. |
2. |
Payment Schedule.
To satisfy the Payment Obligations in full, the Parties agree to the following payment schedule (collectively, the “Payment Schedule”): |
|
a. |
On
or before December 20, 2023, INC will pay to PHARMA $2.791M towards DARM0043, DARM00444, DARM00484 and DARM00429. |
|
i. |
This
sum shall be reduced by any outstanding payments from BIOSCIENCE to INC under Invoice Nos. BioSci
2023-Q3, BioSci 2023-10, and BioSci 2023-09 (currently, approximately $137K). |
|
b. |
On
or before January 31, 2024, INC will pay to PHARMA i) the remainder owed under DARM00429 (approximately $1.4-l.6M), and ii) the full
amount owed under the invoice to be issued by PHARMA in relation to PO# 11440 (estimated at approximately $2.9M). |
|
i. |
This
sum shall be reduced by any outstanding reimbursement from AG to INC for AG’s 50% share of the “Third Installment”
payment under the “Amended Settlement Allocation Agreement” between INC and AG dated March 31, 2023 (currently, $2.815M)
and any outstanding payments from BIOSCIENCE to INC in relation to clinical services provided to BIOSCIENCE in Q4 2023. |
|
c. |
On
or before January 31, 2024, INC will pay to AG invoice AR01207 and to Bioscience invoices No TAR01584 and No.TAR01593. |
|
d. |
On
or before April 30, 2024, INC will pay to PHARMA the agreed upon 2023 PPV and any invoices issued by PHARMA in relation to POs #11272,
#11305, and #11154. |
|
i. |
These
payments shall be contingent on INC and PHARMA’s agreement on the 2023 PPV and PHARMA’s timely delivery of the products
described in POs #11272, #11305, and #11154. |
|
e. |
For
all remaining purchases of “Licensed Products” (as defined by the Agreement) by INC in 2024, INC shall make payment to
PHARMA within the standard payment term described in Section 6.1 of the Agreement. However, if INCfails to make payment in accordance
with Section 6.1 of the Agreement for any reason, INC shall pay the overdue amount to PHARMA within thirty {30) additional days,
in addition to interest calculated in accordance with Section 4.l(d) ofthe Agreement. |
|
|
For
purposes of clarification, for all remaining purchases of Licensed Products by INC in 2024, INC shall not have any rights to any
cure period provided in Section 16.3 other than as set forth in this paragraph 2(d). |
|
a. |
The
Parties agree that INC’s timely completion of payments described in the Payment Schedule will effectively satisfy the Payment
Obligations, in full. As such, so long as INC makes timely payments under the Payment Schedule, AG shall have no |
|
|
grounds
to invoke the provisions of Section 16.3 of the Agreement or otherwise consider INC to be in breach ofthe Agreement due to non-payment
of any Payment Obligations. |
|
|
|
|
|
Notwithstanding
the foregoing, any failure by INC to timely make any payments for “Licensed Products” as defined by the Agreement under
the Payment Schedule shall constitute a material breach pursuant to the Agreement and shall entitle AG to enforce any rights under
the Agreement, including any rights of termination pursuant to Section 16.3 of the Agreement, immediately upon such failure by INC
to make timely payment as defined by Section 2 of this Addendum, irrespective of any cure period provided in Section 16.3 of the
Agreement. |
|
b. |
This
Addendum shall only serve to supplement, amend, and/or modify the Agreement to the extent specifically provided herein. All terms,
conditions, provisions, exhibits and references of and to the Agreement that are not specifically supplemented, amended, and/or modified
herein shall remain in full force and effect and shall not be altered by any provisions herein contained. |
IN
WITNESS WHEREOF, the Parties have executed this Addendum to Amended and Restated License and Supply Agreement as of the date first set
forth above.
BIOFRONTERA AG |
|
BIOFRONTERA INC. |
BIOFRONTERA PHARMA GmbH |
|
|
|
|
|
|
|
|
By: |
/s/
Pilar De La Huerta |
|
By:
|
/s/
Hermann Luebbert |
|
|
|
|
|
Name: |
Pilar De La Huerta |
|
Name: |
Hermann Luebbert |
Title: |
Chief Financial
Officer - Biofrontera AG
|
|
Title: |
Chief
Executive Officer
|
|
Managing Director - Biofrontera
Pharma GmbH |
|
|
|
|
Managing Director - Biofrontera
Bioscience GmbH |
|
|
|
|
|
|
|
|
Date: |
12/12/2023
|
|
Date: |
12/12/2023 |
v3.23.3
Cover
|
Dec. 12, 2023 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Dec. 12, 2023
|
Entity File Number |
001-40943
|
Entity Registrant Name |
Biofrontera
Inc.
|
Entity Central Index Key |
0001858685
|
Entity Tax Identification Number |
47-3765675
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
120
Presidential Way
|
Entity Address, Address Line Two |
Suite 330
|
Entity Address, City or Town |
Woburn
|
Entity Address, State or Province |
MA
|
Entity Address, Postal Zip Code |
01801
|
City Area Code |
(781)
|
Local Phone Number |
245-1325
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Entity Information, Former Legal or Registered Name |
Not
Applicable
|
Common Stock Par Value 0. 001 Per Share [Member] |
|
Title of 12(b) Security |
Common
stock, par value $0.001 per share
|
Trading Symbol |
BFRI
|
Security Exchange Name |
NASDAQ
|
Preferred Stock Purchase Rights [Member] |
|
Title of 12(b) Security |
Preferred
Stock Purchase Rights
|
Security Exchange Name |
NASDAQ
|
Warrants To Purchase Common Stock [Member] |
|
Title of 12(b) Security |
Warrants
to purchase common stock
|
Trading Symbol |
BFRIW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_CommonStockParValue0.001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_PreferredStockPurchaseRightsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=BFRI_WarrantsToPurchaseCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Biofrontera (NASDAQ:BFRI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biofrontera (NASDAQ:BFRI)
Historical Stock Chart
From Apr 2023 to Apr 2024